Pardeep Rihal, MD
Allergy & Immunology · Katy, TXNPI 1982671632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,275 of the $84,972 with a category attached, or 80.4%. GSK accounts for 84.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $22,375 and has fallen 61.3% since, to $8,655 in 2025. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 514 payments — averaging $165.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$72K
- Sanofi$3K
- AstraZeneca$2K
- Optinose US, Inc.$999
- Regeneron Healthcare Solutions, Inc.$717
- Novartis$569
- plus $6K from 29 others
What the payments were for
- Speaking & faculty fees$68,27580%
- Travel & lodging$6921%
- Food & beverage$15,99319%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 182 | $72,019 |
| Sanofi | 79 | $2,510 |
| AstraZeneca | 39 | $1,754 |
| Optinose US, Inc. | 33 | $999 |
| Regeneron Healthcare Solutions, Inc. | 19 | $717 |
| Novartis | 24 | $569 |
| Blueprint Medicines Corporation | 11 | $560 |
| Pfizer | 13 | $541 |
| Genentech USA, Inc. | 14 | $493 |
| Incyte Corporation | 5 | $438 |
| Grifols USA, LLC | 3 | $434 |
| CSL Behring | 15 | $394 |
| Organon | 3 | $349 |
| Alk-abello, Inc | 11 | $322 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $300 |
| Pharming Healthcare, Inc. | 4 | $286 |
| AbbVie | 5 | $271 |
| Genentech, Inc. | 2 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $256 |
| Teva Pharmaceuticals USA, Inc. | 2 | $240 |
| Biocryst US Sales Co., LLC | 6 | $206 |
| Galderma Laboratories, L.p. | 3 | $157 |
| Boehringer Ingelheim | 2 | $150 |
| Cycle Pharmaceuticals Inc | 3 | $135 |
| Shire North American Group Inc | 1 | $108 |
| Sanofi-aventis U.S. LLC | 2 | $91 |
| Amgen | 4 | $84 |
| Johnson & Johnson | 1 | $83 |
| Phadia US Inc. | 1 | $75 |
| Kaleo, Inc. | 2 | $46 |
| Circassia Inc. | 2 | $45 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $17 |
| Covis Pharma GmbH | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,972 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $52,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $37,157 |
| NucalaMepolizumab | 11 | $35,324 |
| XolairOmalizumab | 16 | $21,488 |
| XhanceFluticasone Propionate | 15 | $9,322 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,683 |
| Epinephrine | 18 | $3,498 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 129 | $3,395 |
| Azelastine Hcl | 114 | $3,180 |
| Montelukast Sodium | 192 | $2,039 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,594 |
| Fluticasone Propionate | 87 | $1,401 |
| Ipratropium Bromide | 35 | $656 |
| Ventolin HfaAlbuterol Sulfate | 11 | $586 |
| Levocetirizine Dihydrochloride | 17 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $72,019 | $81,16462 claims |
| Genentech, Inc.Xolair | $267 | $21,48816 claims |
| Optinose US, Inc.Xhance | $999 | $9,32215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Katy
- Chen LinKaty$19K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.